ArticleAnnals of translational medicine2021

Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection.

Hiroaki Kuroda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.